## strategies in other parts of our portfolio.”

By using the growth driver model during the 2022 investment

downturn, Ajax was able to recruit a team of engineers from Nidus

Biomedical that had been struggling to raise venture capital for several

transformative projects. The Nidus team had been pursuing innovations

to address signiﬁcant unmet needs in the acute and chronic heart-

failure spaces, which required large, lengthy, and costly clinical trials.

The team worked with Cordis-X on a series of more manageable projects

that were innovative but more iterative in nature. This approach

brought the team new capital to subsidize its pursuit of those higher

risk, more transformative innovations—thereby satisfying both Ajax’s